• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck partners with Alectos to develop new type of Alzheimer’s treatment

Merck partners with Alectos to develop new type of Alzheimer’s treatment

August 23, 2010
CenterWatch Staff

Merck has launched a research partnership with Alectos Therapeutics, a Vancouver-based biopharmaceutical company, to develop drugs to fight Alzheimer’s Disease based on an enzyme believed to be involved in the development of the disease and potentially other disorders.

Under the agreement, Merck paid Alectos an undisclosed sum upfront and will fund research to study the small Canadian company’s existing portfolio of compounds targeting Alzheimer’s Disease. If Merck develops any of the compounds, Alectos is eligible to receive up to $289 million in upfront fees, research, development and regulatory milestones and tiered royalty payments on sales of products from the collaboration.

Alectos was spun-off from Simon Fraser University in Burnaby, British Columbia, where academic research on the chemical and biological structure of the enzyme, known as O-GlcNAcase, and its role in health and disease led to the development of the compounds.

“This is an important validation of our scientific leadership in this area and we look forward to working with Merck to realize the full value of this novel mechanism for a range of neuroscience disorders,” said Ernest McEachern, Ph.D., Alectos’ CEO.

An estimated 35 proposed Alzheimer’s drugs are in the development pipeline from 30 companies, of which 10 are in phase I, five in phase II and three in phase III. The vast majority of these drugs target amyloid beta, a protein fragment that forms plaques—gummy substances that form filaments that clog the spaces between nerve cells—in the brain that lead to a loss of mental function as billions of neurons begin to die in droves.

While much of the interest in next-generation Alzheimer’s treatments are focused on targeting amyloid plaques, pharmaceutical companies so far have little to show, as there is no treatment available to halt the progression of the debilitating disease that affects 5.3 million Americans.

Major companies including Pfizer, Johnson & Johnson and Elan Pharmaceuticals and their partners have struggled to develop Alzheimer’s drugs. Just last week Eli Lilly announced it was halting development of semagacestat, a gamma secretase inhibitor, because preliminary results from two phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

Even Merck 21 months ago terminated further testing in humans of a growth hormone which had shown encouraging results in mice but did not appear to reduce human symptoms of Alzheimer’s Disease.

“The recent failure of amyloid-beta-targeted therapies in phase III clinical trials suggest that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer’s Disease,” Kurt R. Brunden, Ph.D., research associate professor of pathology and laboratory medicine at the University of Pennsylvania School of Medicine, wrote in a research paper last October.

Now Merck, headquartered in Whitehouse Station, N.J., is betting that Alectos’ different approach will lead to success.

“Effective medicines to treat the devastating consequences of Alzheimer’s Disease are greatly needed, and we are committed to achieve that goal,” said Darryle Schoepp, senior vice president and franchise head of neuroscience at Merck Research Laboratories. “This collaboration represents a truly innovative and promising new therapeutic approach in the Alzheimer’s Disease field.”

—Ronald Rosenberg

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing